Top Boston, MA Biotech Companies With Best Stability & Growth (307)
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform...
SOPHiA GENETICS's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue continues to rise at a double‑digit pace year over year with acceleration into year‑end. Management reaffirmed guidance for another year of meaningful top‑line expansion.
Market Expansion: The customer base and analysis volumes increased to record levels, and two large U.S. integrated health systems are expected to add substantial annual throughput as implementations ramp in the second half of 2026. Net dollar retention improved, indicating deeper adoption within existing institutions.
Strategic Partnerships: Collaborations with leading cancer centers and biopharma (e.g., MSK‑ACCESS powered with SOPHiA DDM, AstraZeneca, MD Anderson) are expanding product adoption and opening key U.S. channels. These alliances signal validation of the platform and support growth in high‑value applications like liquid biopsy.
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Fresh capital includes a $50M Series D on April 9, 2026 led by Boehringer Ingelheim and a 2025 Series C with Dassault Systèmes/Medidata to fund commercialization and platform scaling. Feedback suggests these transactions reflect strong external confidence and provide runway to advance regulatory and launch efforts.
Product Line Growth: Multiple FDA authorizations (Rejoyn in 2024; CT‑132 in 2025), positive Phase 3 data for CT‑155, and acquisition of Better Therapeutics’ assets expand the portfolio across psychiatry, neurology, and cardiometabolic conditions. A 2026 Ultrahuman partnership further extends migraine technology into adjacent offerings.
Strategic Partnerships: Multi‑year collaborations with Boehringer Ingelheim and Otsuka, plus ecosystem ties with Dassault Systèmes/Medidata and Ultrahuman, underpin development and prospective commercialization. These alliances distribute risk and provide capabilities and channels that many peers lack.
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
Benchling's Top Stability & Growth Strengths
Strong Revenue Growth: ARR was estimated around $200M+ by mid-2024 with year-over-year increases, alongside a larger customer base and higher revenue per customer. These signals indicate ongoing expansion in core subscription economics.
Strategic Partnerships: An expanded collaboration with Moderna bringing hundreds of scientists onto a unified, AI-ready environment signals deepening penetration in large biopharma accounts. Such marquee expansions reinforce credibility and create room for further account growth.
Product Line Growth: The company has shipped frequent platform updates, launched AI capabilities, and integrated partners like NVIDIA NIM, while adding offerings such as Benchling Bioprocess and via the PipeBio acquisition. This broadens the product surface area and supports land-and-expand motions.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability & Growth Strengths
Strong Revenue Growth: Reported total net revenue rose from $693.4 million in 2024 to about $1.27 billion in 2025, with Q4 2025 also showing strong year‑over‑year growth. Management guides 2026 revenue to roughly $1.59 billion, indicating continued expansion.
Customer Loyalty & Retention: Disclosed net revenue retention of approximately 126% and total remaining contract value exceeding $1.1 billion signal expanding multi‑year demand. These metrics indicate existing customers are increasing spend and extending commitments.
Strategic Partnerships: Multi‑year collaborations with major pharmas and health systems—including a three‑year, $200 million data/modeling agreement with AstraZeneca/Pathos and an expanded Merck collaboration—support growth in data licensing and AI applications. Partnerships with top‑tier sponsors evidence strong demand for the platform.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenue increased meaningfully year over year, with software higher and drug‑discovery contributions expanding. Management also guides continued expansion into 2026 as measured by software ACV.
Strategic Partnerships: Large, multi‑target collaborations (e.g., with Novartis) and integrations with leading pharmas (e.g., Lilly) reinforce commercial traction and ecosystem reach. These relationships support both recurring software usage and potential milestone‑driven upside.
Future-Ready Strategy: Accelerating the shift from on‑premise to hosted licensing is intended to make revenue more predictable and better align recognition with contract value. 2026 priorities emphasize platform scaling, new offerings like predictive toxicology, and deeper partner integrations.
Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we’re built...
Genevant is a technology-focused nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate and decades of expertise in nucleic acid drug development. We leverage our world-class delivery systems and related technologies to bring new medicines to patients who need them. We do this by selectively collaborating with leading pharma and biotech...
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes across oncology, neurology and cardiology. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years.
We work at the frontier of programmable medicines. We power our bioplatform and product candidates by harnessing evolution and AI. We operate with purpose and urgency on behalf of people everywhere. We aim to generate life-changing impact for the world
Valence Labs, powered by Recursion, is industrializing scientific discovery to radically improve lives. Our vision is that highly autonomous systems capable of Nobel-worthy insights will usher in a new wave of scientific discovery. Following the acquisition of Valence Discovery by Recursion (NASDAQ: RXRX) in May 2023, Valence Labs continues as a semi-autonomous AI research engine within Recursion aiming to advance...
Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in allergic disease treatment. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases. Poplar is pursuing the bold idea that IgE can be rapidly driven toward zero, with the goal of helping...
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology...
Pillar Biosciences was founded in 2014, on the principle that in order for personalized medicine to be realized, clinical Next Generation Sequencing (NGS) workflows need to be affordable, rapid, robust, and flexible. We’re focused on productive solutions that enable streamlined workflows, so that labs can generate dependable results with less inputs, less labor, and less time. Our team makes precision...
Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely...
Endpoint Clinical, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is repeatedly characterized as a global leader in RTSM/IRT with substantial operating scale, supporting 2,000+ studies across 90+ countries and 800+ active studies. This breadth and ability to handle complex, global trials provide a durable competitive edge.
Investor Backing & Capital Strength: The June 2024 acquisition by Arsenal Capital Partners supplies focused capital and sponsor support to accelerate expansion and innovation. This backing is presented as validation of market position and a catalyst for the next phase of growth.
Innovation-Driven Growth: Five generations of purpose-built RTSM platforms and the proprietary PULSE platform, including faster study builds in four weeks or less, indicate sustained product advancement. A 2025 brand refresh and continued tech investment underscore a roadmap aimed at pushing RTSM forward.
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Our lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). We are also advancing an early-stage portfolio...
Dragonfly Therapeutics is a clinical-stage biotech developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing...
At Ark, we are transforming bioprocessing by championing a model-first approach that combines biology, chemistry, and physics with the predictive power of machine learning and AI. By replacing traditional trial-and-error methods with hybrid models, we empower organizations to predict outcomes, optimize processes, and scale with precision—dramatically reducing R&D timelines, cutting costs, and increasing accessibility to life-saving therapies and innovative products....
Landmark Bio is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing...
Podimetrics is a virtual care management company dedicated to preventing costly and deadly diabetic amputations. We provide high-risk patients our FDA-cleared SmartMat™ through partnerships with payers and at-risk providers, including the Veterans Health Administration. After placing their feet on the mat for just 20 seconds a day, patients’ data are automatically sent to our care management team, which helps address...
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and...
